DVS Sciences announces business agreement with Cytobank

NewsGuard 100/100 Score

DVS Sciences, Inc., a privately held innovator and manufacturer of novel CyTOF® multi-parameter single-cell analyzers and reagents for biological research, today announced a business agreement with Cytobank, Inc., a privately held developer of cloud based scientific, informatics and software solutions for the flow cytometry market.    

The CyTOF mass cytometry platform developed by DVS Sciences enables revolutionary understanding of cellular dynamics of disease states, identification of stem cells and unprecedented insight into other biological systems using metal conjugated antibodies bound to cells and analyzed by time of flight mass spectrometry. The technology uniquely has the capability to simultaneously measure up to 100 cell biomarkers in single cells at up to 1000 cells per second. The software platform created by Cytobank enables researchers to analyze and manage the data acquired on CyTOF instruments using a novel cloud computing platform integrated with proprietary algorithms for data analysis. Together, DVS Sciences and Cytobank will co-develop and release an integrated solution, "DVS Cytobank™", that automatically analyzes and manages the large data sets resulting from CyTOF instruments, while concurrently providing information on reagent panels and protocols. The new venture enables and simplifies the analysis of the massively multi-parameter mass cytometry data. DVS Cytobank is a proprietary implementation developed specifically for mass cytometry data, capitalizing on the Cytobank platform and provided by DVS Sciences directly to researchers using the CyTOF platform.

"The marriage of uniquely informative data acquired by our CyTOF instruments and reagents with the powerful capabilities of the Cytobank cloud based platform will be enabling for our researchers around the world as they analyze, manage, and share large amounts of multi-parameter data," says Joseph Victor, President & CEO of DVS Sciences. Nikesh Kotecha, Ph.D , CEO & Co-founder of Cytobank adds, "we are excited to be partnering with DVS Sciences to create a software solution that enables the next generation of high dimensional cytometry and single cell systems biology brought about by the CyTOF instrument."

An early access version of DVS Cytobank will be released to the customers of DVS Sciences in August with a formal release available by November, 2012.

Source:

DVS Sciences, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists map all yeast proteins across cell cycle for the first time